Core Viewpoint - Antu Biology's net profit attributable to shareholders for the first three quarters of 2025 is 860 million yuan, a year-on-year decrease of 10.11% [1] - The company continues to deepen its multi-field layout despite short-term performance pressure [1] Financial Performance - The net profit for the third quarter is 289 million yuan, reflecting a year-on-year decline of 14.30% [1] - The company's gross margin has slightly decreased, while the expense ratio remains stable [1] Product Development - The company has launched three products in the bacterial triad detection category, with the nucleic acid test for "Onion Burkholderia" being the first in China to obtain registration [1] - These products can be integrated with fully automated nucleic acid purification and real-time fluorescence PCR analysis systems, enhancing the molecular respiratory product line [1] Instrumentation and Technology - Antu Biology has successfully introduced a series of liquid chromatography-tandem mass spectrometry products, including the AutomS TQ6000 detection system and fully automated sample pretreatment equipment [1] - The wholly-owned subsidiary, Sikun Biology, has completed the product layout for the Sikun series, launching four gene sequencers and an automated pathogen analysis system, successfully entering the non-clinical market [1] - The fully automated gene sequencing library preparation instrument, AISPre3200, has entered the trial production stage [1] Investment Rating - The company maintains a "Buy" rating despite the current performance challenges [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 2.06 billion yuan in the first half of 2025, a year-over-year decrease of 6.65%, with a net profit attributable to shareholders of 571 million yuan, down 7.83% year-over-year [4] - In Q2 2025, the company achieved a revenue of 1.064 billion yuan, a year-over-year decrease of 4.79%, but the net profit attributable to shareholders increased by 1.97% year-over-year to 301 million yuan [5] - The company has seen a marginal improvement in performance, with a significant reduction in expense ratios, leading to a recovery in profitability [5] Summary by Sections Financial Performance - In Q2 2025, the company reported a quarter-on-quarter revenue increase of 6.9% and a year-over-year net profit growth of 1.97% [5] - The operating cash flow for Q2 2025 was 244 million yuan, reflecting a year-over-year increase of 45.9% [4] - The company’s revenue from domestic operations in H1 2025 was 1.904 billion yuan, down 8.32% year-over-year, while overseas revenue was 157 million yuan, up 19.78% year-over-year [5] Research and Development - The company maintained high R&D investments, with expenditures of 571.69 million yuan, 656.13 million yuan, and 731.93 million yuan from 2022 to 2024, representing 12.87%, 14.77%, and 16.37% of revenue respectively [6] - In H1 2025, the company obtained 88 new reagent certificates covering various diagnostic methods [6] Future Projections - Revenue projections for 2025 to 2027 are 4.501 billion yuan, 4.975 billion yuan, and 5.531 billion yuan, with year-over-year growth rates of approximately 0.7%, 10.5%, and 11.2% respectively [8] - Net profit attributable to shareholders is expected to reach 1.22 billion yuan, 1.403 billion yuan, and 1.617 billion yuan for the same period, with growth rates of 2.2%, 14.9%, and 15.3% respectively [8]